St Vincent’s Institute of Medical Research New Clinical Trial

13 Nov 2020

Captixbio’s partner, SVI, are leading a new clinical trial – The BANDIT Trial – which will test the effectiveness of the drug, baricitinib, in stopping the immune system from destroying the insulin-producing cells of type 1 diabetes patients with recent diagnoses. Participants with type 1 diabetes aged between 12-30 years old and who have diagnosed in the last 100 days are being recruited.

More information is available at: